# Pharma Competitive Intelligence

> A reference on pharmaceutical competitive intelligence practice: how CI teams track
> pipelines at indication level, cover oncology congresses, and combine published
> sources with primary expert research to support commercial decisions.

Draws on publicly available material only — trial registries, congress proceedings,
regulatory documents and company disclosure. Not clinical, regulatory, legal or
investment advice.

Articles are written by Delores Wong.

## Articles

- [What is pharmaceutical competitive intelligence?](https://pharmacompetitiveintelligence.com/blog/what-is-pharmaceutical-competitive-intelligence.html): The scope, the deliverables, who consumes them, and the distinction between intelligence and a pile of collected documents.
- [Why oncology CI is a different job](https://pharmacompetitiveintelligence.com/blog/oncology-competitive-intelligence.html): Oncology competitive intelligence has to be tracked at indication, line-of-therapy and biomarker level. Here is why tumour-type tracking fails and what the gran
- [Congress intelligence: the abstract-to-podium cycle](https://pharmacompetitiveintelligence.com/blog/conference-intelligence-asco-esmo-aacr.html): How pharma CI teams cover oncology congresses: the abstract release and embargo cycle, why presented data differs from the abstract, late-breakers, and what to 
- [Primary vs secondary intelligence](https://pharmacompetitiveintelligence.com/blog/primary-vs-secondary-intelligence-pharma.html): The difference between secondary and primary competitive intelligence in pharma, what each source type can and cannot answer, and how to combine them without pa
- [Pre-launch competitive intelligence](https://pharmacompetitiveintelligence.com/blog/pre-launch-competitive-intelligence.html): What competitive intelligence has to deliver in the two years before a pharmaceutical launch: competitor launch sequencing, anticipated labels, access starting 
- [CI for business development and licensing](https://pharmacompetitiveintelligence.com/blog/ci-for-bd-and-licensing.html): How competitive intelligence supports pharmaceutical in-licensing and acquisition diligence: defining the comparator set, forecasting standard of care at launch
- [LOE and biosimilar intelligence](https://pharmacompetitiveintelligence.com/blog/loss-of-exclusivity-biosimilar-intelligence.html): How CI teams track generic and biosimilar entry: the signals available under Hatch-Waxman versus the BPCIA, why biosimilar erosion behaves nothing like generic 
- [CI tools and databases](https://pharmacompetitiveintelligence.com/blog/pharma-ci-tools-and-databases.html): A practical guide to the pharmaceutical competitive intelligence software and data market: what each category of subscription is genuinely good at, the four que
- [The registry is a primary source — if you read the changes](https://pharmacompetitiveintelligence.com/blog/clinicaltrials-gov-competitive-intelligence.html): How pharma CI teams actually use ClinicalTrials.gov: which record fields carry competitive signal, why the change history matters more than the record itself, a
- [What a CI report actually contains](https://pharmacompetitiveintelligence.com/blog/pharma-ci-report-structure.html): The structure of a pharmaceutical competitive intelligence report: the five deliverable types, a section-by-section anatomy, sensible cadence, and why most CI d
- [Automation in CI: an honest division of labour](https://pharmacompetitiveintelligence.com/blog/ai-automation-pharma-ci.html): Which parts of pharmaceutical competitive intelligence automate well — registry diffs, abstract triage, alert routing — which parts do not, and how to use LLMs 

## Site

- [About](https://pharmacompetitiveintelligence.com/about.html)
- [All articles](https://pharmacompetitiveintelligence.com/blog/)